Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0HGQF5
Tue, 20.07.2021
MagForce AG
- Approval for prostate treatment imminent,
- New treatment devices to be installed in Europe,
- Strong growth and break-even expected from 2022 onwards
Despite pandemic-related restrictions, MagForce AG made further progress in
2020 in the commercialisation of its own technology. For the alreadyapproved
treatment of malignant brain tumours in [ … ]
Wed, 30.06.2021
MagForce AG
MagForce AG Publishes Financial Results for the Year 2020 and Operative Highlights
- Europe: High growth in treatment numbers beginning of 2020 - after severe COVID-19 impact European roll-out now picks up speed again
- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer completed - additional dat [ … ]
Mon, 07.06.2021
MagForce AG
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
Berlin, Germany, and Nevada, USA, June 7, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, o [ … ]
Thu, 29.04.2021
MagForce AG
Further results of the pivotal study 2a confirm expectations, market
approval in 2021 still in prospect, price target of EUR 11.00 and BUY
rating confirmed
After MagForce AG announced the successful completion of stage 2a of the
pivotal study for the treatment of prostate cancer in the USA in February
2021, the company has published additional, [ … ]
Mon, 26.04.2021
MagForce AG
MagForce Announces Additional Supportive Data from Stage 2a of its Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System
- Further analysis of the Stage 2a results confirm positive initial findings published in February of this year - treatment-related side effects remained min [ … ]
Fri, 18.12.2020
MagForce AG
Capital increase of EUR4.7m successfully implemented to finance growth
strategy, high share price potential, BUY rating confirmed
Since our last research study (see research study dated 12.11.2020), the
share price of MagForce AG has developed significantly positively. Within
just one month, the share price has risen significantly by approximate [ … ]
Tue, 15.12.2020
MagForce AG
MagForce AG Successfully Completes Private Placement of New Shares
- Placement of 1.165 million shares or 4.2 percent of the share capital
- Gross proceeds of approx. EUR 4.7 million
Berlin and Nevada, December 15, 2020 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedici [ … ]
Tue, 15.12.2020
MagForce AG
Publication of Inside Information according to Article 17 MAR
MagForce AG Successfully Places 1,165 Million New Shares Through Cash Capital Increase with Gross Proceeds of approx. 4.7 Million EUR
NOT FOR DIRECT OR INDIRECT DISTRIBUTION OR PUBLICATION IN THE USA OR IN OR INTO CANADA, AUSTRALIA OR JAPAN OR OTHER COUNTRIES WHERE SUCH DISTRIBUTION OR [ … ]
Thu, 10.12.2020
MagForce AG
Publication of Inside Information according to Article 17 MAR
MagForce AG Launches Capital Increase with Exclusion of Subscription Rights from Authorized Capital
NOT FOR DIRECT OR INDIRECT DISTRIBUTION OR PUBLICATION IN THE USA OR IN OR INTO CANADA, AUSTRALIA OR JAPAN OR OTHER COUNTRIES WHERE SUCH DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL
B [ … ]
Tue, 08.12.2020
MagForce AG
MagForce AG Announces Opening of New NanoTherm Treatment Center for Brain Tumor Patients at Mühlhausen Hufeland Clinic in Thuringia, Germany
All audits of the new NanoTherm treatment center at the Mühlhausen Hufeland Clinic have been completed, first patients are anticipated to be treated in December 2020
The center is managed by PD Dr. Johannes [ … ]